Maxim Group Reiterates Buy Rating for BIOLINERX LTD/S (NASDAQ:BLRX)

BIOLINERX LTD/S (NASDAQ:BLRX)‘s stock had its “buy” rating reiterated by equities research analysts at Maxim Group in a research note issued to investors on Monday, reports. They presently have a $10.00 price target on the biotechnology company’s stock. Maxim Group’s price target would indicate a potential upside of 168.82% from the stock’s current price.

Several other analysts have also recently issued reports on BLRX. HC Wainwright set a $25.00 target price on shares of Onconova Therapeutics and gave the company a “buy” rating in a research report on Tuesday, May 14th. Zacks Investment Research upgraded shares of Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Tuesday, July 16th. Finally, ValuEngine upgraded shares of Vale from a “sell” rating to a “hold” rating in a research report on Tuesday, July 16th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. BIOLINERX LTD/S has an average rating of “Buy” and an average price target of $4.13.

Shares of NASDAQ BLRX opened at $3.72 on Monday. The firm’s 50-day simple moving average is $1.02. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.12 and a quick ratio of 5.12. The stock has a market cap of $27.82 million, a PE ratio of -1.18 and a beta of 1.53. BIOLINERX LTD/S has a 12-month low of $3.47 and a 12-month high of $27.60.

BIOLINERX LTD/S (NASDAQ:BLRX) last announced its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). On average, equities analysts forecast that BIOLINERX LTD/S will post -2.55 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in BLRX. Two Sigma Securities LLC purchased a new stake in BIOLINERX LTD/S in the 4th quarter worth about $25,000. Deutsche Bank AG purchased a new stake in BIOLINERX LTD/S in the 4th quarter worth about $26,000. NEXT Financial Group Inc raised its position in BIOLINERX LTD/S by 82.5% in the 2nd quarter. NEXT Financial Group Inc now owns 73,000 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 33,000 shares during the period. Finally, Delek Group Ltd. purchased a new stake in BIOLINERX LTD/S in the 1st quarter worth about $92,000.


BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.

Recommended Story: Fiduciary

Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with's FREE daily email newsletter.